FP
LGND icon

Foundry Partners’s Ligand Pharmaceuticals LGND Stock Holding History

Foundry Partners’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-13,706
Closed -$815K – 437
2020
Q3 		$815K Sell
13,706
-176
-1% -$12K 0.04% 331
2020
Q2 		$969K Sell
13,882
-527
-4% -$33.4K 0.05% 307
2020
Q1 		$654K Hold
14,409
– – 0.04% 326
2019
Q4 		$937K Sell
14,409
-343
-2% -$22.9K 0.04% 325
2019
Q3 		$916K Sell
14,752
-34
-0.2% -$2.13K 0.04% 322
2019
Q2 		$1.05M Sell
14,786
-43
-0.3% -$3.17K 0.04% 313
2019
Q1 		$1.16M Buy
14,829
+2,455
+20% +$186K 0.05% 310
2018
Q4 		$1.05M Buy
+12,374
New +$1.32M 0.05% 315

Other funds holding LGND

William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CCMLC
Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
CCA
Conestoga Capital Advisors Wayne, Pennsylvania $5.01B AUM 6.26% 1-Year Est. Return
SDJVC
St. Denis J. Villere & Co New Orleans, Louisiana $907M AUM 10.61% 1-Year Est. Return

Foundry Partners's LGND Position: Q4 2020 in Review

Foundry Partners sold out of Ligand Pharmaceuticals (LGND) in Q4 2020, closing a stake of 13,706 shares — an estimated $815K sold.

Foundry Partners first reported a position in LGND in Q4 2018 and held it in 8 quarters. The position peaked at $1.16M in Q1 2019. 242 funds tracked by Wall St. Rank hold LGND as of Q4 2020.

  • Foundry Partners reported no remaining Ligand Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
  • Foundry Partners sold 13,706 Ligand Pharmaceuticals shares in Q4 2020, an estimated $815K.
  • Foundry Partners first reported a position in Ligand Pharmaceuticals in Q4 2018 and held it in 8 quarters.
  • Foundry Partners's Ligand Pharmaceuticals position peaked at $1.16M in Q1 2019.
  • 242 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q4 2020.

Based on Foundry Partners's 13F filing for Q4 2020, filed 4 Feb 2021.